Domů › Mnohočetný myelom › North Carolina › Durham
Klinické studie Mnohočetný myelom v Durham, NC
37 studií pro Mnohočetný myelom hledá účastníky v lokalitách v Durham a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Probíhá náborFáze 3
- Research Site, Chapel Hill · Vzdálenost 10 mi
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Probíhá náborFáze 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · Vzdálenost 10 mi
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Probíhá náborFáze 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Probíhá náborFáze 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · Vzdálenost 10 mi
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Probíhá náborFáze 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Probíhá náborFáze 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 2
- University of North Carolina Medical Center, Chapel Hill · Vzdálenost 10 mi
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Probíhá náborFáze 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · Vzdálenost 10 mi
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Probíhá náborFáze 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · Vzdálenost 13 mi
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Probíhá náborFáze 1/2
- GSK Investigational Site, Chapel Hill · Vzdálenost 10 mi
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Probíhá náborFáze 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Probíhá náborFáze 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Probíhá náborFáze 3
- Research Site, Durham
- Research Site, Chapel Hill · Vzdálenost 10 mi
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Probíhá nábor
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · Vzdálenost 10 mi
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Probíhá náborFáze 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · Vzdálenost 10 mi
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Probíhá náborFáze 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · Vzdálenost 10 mi
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Probíhá náborFáze 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- University of North Carolina /ID# 251203, Chapel Hill · Vzdálenost 10 mi
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Probíhá náborFáze 1
- University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Probíhá náborFáze 2
- University of North Carolina (Data Collection Only), Chapel Hill · Vzdálenost 10 mi
Registry of Older Patients With Cancer
Probíhá náborObservační studie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Vzdálenost 10 mi
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Probíhá náborFáze 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Probíhá náborFáze 2
- University of North Carolina, Chapel Hill · Vzdálenost 10 mi
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Probíhá náborFáze 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Probíhá náborFáze 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · Vzdálenost 10 mi
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Probíhá náborFáze 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · Vzdálenost 13 mi
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Probíhá náborFáze 1
- University of North Carolina, Chapel Hill · Vzdálenost 10 mi
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Probíhá náborFáze 1
- University of North Carolina, Chapel Hill · Vzdálenost 10 mi
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Probíhá náborFáze 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · Vzdálenost 10 mi
Registry for Adults With Plasma Cell Disorders (PCD's)
Probíhá náborObservační studie
- North Carolina Cancer Hospital, Chapel Hill · Vzdálenost 10 mi
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Probíhá náborObservační studie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Vzdálenost 10 mi
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 1
- Duke University Health System (DUHS), Durham
Studie Mnohočetný myelom v jiných městech
- New York City, NY60 studií
- Boston, MA42 studií
- Atlanta, GA41 studií
- Houston, TX38 studií
- Nashville, TN32 studií
- Denver, CO27 studií
- Rochester, MN24 studií
- St. Louis, MO24 studií
- Columbus, OH24 studií
- Baldwin Park, CA23 studií
- Chicago, IL22 studií
- Seattle, WA22 studií
Další studie v Durham
- Rakovina prsu63 studií
- Rakovina (všechny typy)58 studií
- Nemalobuněčný plicní karcinom39 studií
- Metastatický karcinom33 studií
- Akutní myeloidní leukemie33 studií
- Rakovina plic32 studií
- Rakovina prostaty32 studií
- Kolorektální karcinom28 studií
- Chronická lymfocytární leukemie27 studií
- Rakovina vaječníků27 studií
- Srdeční selhání26 studií
- Rakovina slinivky břišní24 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.